Rallybio Corporation(RLYB)Earnings, Financials & Key Ratios
RLYB•NASDAQ
$14.56
$82M mkt cap·Price updated May 6, 2026
AboutRallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.Show more
- Revenue$636K
- EBITDA-$60M+23.4%
- Net Income-$58M+22.5%
- EPS (Diluted)-10.64+27.7%
- Gross Margin100%
- EBITDA Margin-9491.35%
- Operating Margin-9511.95%
- Net Margin-9084.12%
- ROE-68.85%-27.2%
- ROIC-69.81%-15.0%
- Debt/Equity0.00-32.3%
RLYB Key Insights
Rallybio Corporation (RLYB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓Trading near 52-week high
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RLYB Price & Volume
Rallybio Corporation (RLYB) stock price & volume — 10-year historical chart
Loading chart...
RLYB Growth Metrics
Rallybio Corporation (RLYB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-18.4%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM78.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM79.69%
Return on Capital
10 Years-54.95%
5 Years-46.12%
3 Years-56.14%
Last Year-71.92%
RLYB Recent Earnings
Rallybio Corporation (RLYB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 3/12 qtrs (75%)
Q4 2025Latest
Nov 6, 2025EPS
$0.14
Est $0.25
+44.0%
Revenue
$212,000
Est $66,667
+218.0%
Q3 2025
Aug 7, 2025EPS
$0.22
Est $0.20
-12.8%
Revenue
$212,000
Est $66,670
+218.0%
Q2 2025
May 8, 2025EPS
$0.21
Est $0.21
+0.0%
Revenue
$212,000
Q2 2025
Mar 13, 2025EPS
$0.25
Est $0.27
+7.4%
Revenue
$38,000
Est $149,500
-74.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 6, 2025 | $0.14vs $0.25+44.0% | $212,000vs $66,667+218.0% |
| Q3 2025 | Aug 7, 2025 | $0.22vs $0.20-12.8% | $212,000vs $66,670+218.0% |
| Q2 2025 | May 8, 2025 | $0.21vs $0.21+0.0% | $212,000 |
| Q2 2025 | Mar 13, 2025 | $0.25vs $0.27+7.4% | $38,000vs $149,500-74.6% |
Based on last 12 quarters of dataView full earnings history →
RLYB Peer Comparison
Rallybio Corporation (RLYB) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 TPST | 56.36M | 2.02 | -1.35 | -5.68% | 0.80 | |||
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% |
Compare RLYB vs Peers
Rallybio Corporation (RLYB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RLYB Income Statement
Rallybio Corporation (RLYB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 636K | 674K |
| Revenue Growth % | - | - | - | - | - | - | -18.4% |
| Cost of Goods Sold | 26.34K | 62.03K | 109K | 167K | 150K | 0 | 65K |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -26.34K▲ 0% | -62.03K▼ 135.5% | -109K▼ 75.7% | -167K▼ 53.2% | -150K▲ 10.2% | 636K▲ 524.0% | 644K▲ 0% |
| Gross Margin % | - | - | - | - | - | 100% | 95.55% |
| Gross Profit Growth % | - | -135.46% | -75.72% | -53.21% | 10.18% | 524% | - |
| Operating Expenses | 17.64M | 25.3M | 45.65M | 67.88M | 78.93M | 61.13M | 38.9M |
| OpEx % of Revenue | - | - | - | - | - | 9611.95% | - |
| Selling, General & Admin | 6.28M | 7.67M | 18.74M | 27.2M | 25.39M | 19.63M | 15.61M |
| SG&A % of Revenue | - | - | - | - | - | 3085.69% | - |
| Research & Development | 11.37M | 17.63M | 26.91M | 40.69M | 53.54M | 41.51M | 23.3M |
| R&D % of Revenue | - | - | - | - | - | 6526.26% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -17.64M▲ 0% | -25.3M▼ 43.4% | -45.65M▼ 80.4% | -67.88M▼ 48.7% | -78.93M▼ 16.3% | -60.5M▲ 23.4% | -38.26M▲ 0% |
| Operating Margin % | - | - | - | - | - | -9511.95% | -5676.56% |
| Operating Income Growth % | - | -43.42% | -80.41% | -48.71% | -16.27% | 23.36% | - |
| EBITDA | -17.62M | -25.24M | -45.54M | -67.72M | -78.78M | -60.37M | -38.14M |
| EBITDA Margin % | - | - | - | - | - | -9491.35% | -5658.9% |
| EBITDA Growth % | - | -43.29% | -80.42% | -48.7% | -16.34% | 23.38% | 45.41% |
| D&A (Non-Cash Add-back) | 26.34K | 62K | 109K | 167K | 150K | 131K | 119K |
| EBIT | -17.42M | -25.3M | -45.5M | -67.88M | -78.93M | -60.5M | -38.26M |
| Net Interest Income | 158K | 122K | 44K | 1.96M | 6.15M | 4.22M | 2.44M |
| Interest Income | 197K | 171K | 54K | 1.96M | 6.15M | 4.22M | 2.44M |
| Interest Expense | 39K | 49K | 10K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 79K | -1.16M | -1.36M | 1.23M | 4.37M | 2.72M | 24.09M |
| Pretax Income | -17.46M▲ 0% | -26.46M▼ 51.6% | -47.01M▼ 77.7% | -67.73M▼ 44.1% | -74.56M▼ 10.1% | -57.77M▲ 22.5% | -14.17M▲ 0% |
| Pretax Margin % | - | - | - | - | - | -9084.12% | -2102.37% |
| Income Tax | 0 | -15K | 0 | -1.07M | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0.06% | 0% | 1.59% | 0% | 0% | 0% |
| Net Income | -17.63M▲ 0% | -26.45M▼ 50.0% | -47.01M▼ 77.8% | -66.65M▼ 41.8% | -74.56M▼ 11.9% | -57.77M▲ 22.5% | -14.17M▲ 0% |
| Net Margin % | - | - | - | - | - | -9084.12% | -2102.37% |
| Net Income Growth % | - | -50.05% | -77.76% | -41.78% | -11.87% | 22.52% | 78.84% |
| Net Income (Continuing) | -17.56M | -26.45M | -47.01M | -66.65M | -74.56M | -57.77M | -14.17M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.32▲ 0% | -9.52▼ 50.6% | -11.68▼ 22.7% | -16.72▼ 43.2% | -14.72▲ 12.0% | -10.64▲ 27.7% | -2.52▲ 0% |
| EPS Growth % | - | -50.63% | -22.69% | -43.15% | 11.96% | 27.72% | 79.69% |
| EPS (Basic) | -4.40 | -9.52 | -11.68 | -16.72 | -14.72 | -10.64 | - |
| Diluted Shares Outstanding | 2.78M | 2.78M | 4.02M | 3.98M | 5.06M | 5.44M | 5.63M |
| Basic Shares Outstanding | 2.78M | 2.78M | 4.02M | 3.98M | 5.06M | 5.44M | 5.63M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
RLYB Balance Sheet
Rallybio Corporation (RLYB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 20.92M | 141.26M | 180.87M | 179.5M | 114.79M | 67.84M | 66.63M |
| Cash & Short-Term Investments | 19.46M | 140.23M | 175.33M | 168.99M | 109.93M | 65.51M | 59.32M |
| Cash Only | 19.46M | 140.23M | 175.33M | 56.96M | 24.49M | 13.9M | 32.12M |
| Short-Term Investments | 0 | 0 | 0 | 112.04M | 85.44M | 51.61M | 27.2M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 395K | 1.05M | 2.05M | 995K | 7.31M |
| Total Non-Current Assets | 687K | 597K | 1.32M | 939K | 831K | 267K | 1.03M |
| Property, Plant & Equipment | 199K | 287K | 511K | 909K | 592K | 267K | 224K |
| Fixed Asset Turnover | - | - | - | - | - | 2.38x | 3.40x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 488K | 310K | 805K | 30K | 239K | 0 | 1.04M |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 810K |
| Total Assets | 21.61M▲ 0% | 141.86M▲ 556.5% | 182.19M▲ 28.4% | 180.44M▼ 1.0% | 115.62M▼ 35.9% | 68.11M▼ 41.1% | 67.66M▲ 0% |
| Asset Turnover | - | - | - | - | - | 0.01x | 0.01x |
| Asset Growth % | - | 556.54% | 28.43% | -0.96% | -35.92% | -41.09% | -141.92% |
| Total Current Liabilities | 3.81M | 5.84M | 6.55M | 10.74M | 9.26M | 6.24M | 4.52M |
| Accounts Payable | 857K | 1.58M | 603K | 1.11M | 976K | 278K | 269K |
| Days Payables Outstanding | 11.87K | 9.29K | 2.02K | 2.43K | 2.37K | - | 1.5K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 848K | 2.76M |
| Other Current Liabilities | 1.59M | 0 | 2.99M | 4.7M | 3.17M | 3.1M | 3.74M |
| Current Ratio | 5.50x | 24.18x | 27.61x | 16.71x | 12.39x | 10.87x | 10.87x |
| Quick Ratio | 5.50x | 24.18x | 27.61x | 16.71x | 12.39x | 10.87x | 10.87x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 941K | 12K | 32K | 374K | 173K | 212K | 108K |
| Long-Term Debt | 0 | 0 | 0 | 374K | 0 | 0 | 108K |
| Capital Lease Obligations | 0 | 0 | 0 | 374K | 173K | 0 | 108K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 941K | 12K | 32K | -374K | 0 | 0 | -108K |
| Total Liabilities | 4.75M | 5.86M | 6.58M | 11.12M | 9.44M | 6.45M | 4.63M |
| Total Debt | 0 | 0 | 0 | 555K | 392K | 154K | 198K |
| Net Debt | -19.46M | -140.23M | -175.33M | -56.4M | -24.1M | -13.75M | -31.92M |
| Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | 0.84x |
| Interest Coverage | -452.36x | -516.39x | -4564.80x | - | - | - | - |
| Total Equity | 16.86M▲ 0% | 136M▲ 706.7% | 175.6M▲ 29.1% | 169.32M▼ 3.6% | 106.18M▼ 37.3% | 61.65M▼ 41.9% | 63.03M▲ 0% |
| Equity Growth % | - | 706.66% | 29.12% | -3.58% | -37.29% | -41.94% | -134.84% |
| Book Value per Share | 6.06 | 48.91 | 43.72 | 42.57 | 21.00 | 11.33 | 11.19 |
| Total Shareholders' Equity | 16.86M | 136M | 175.6M | 169.32M | 106.18M | 61.65M | 63.03M |
| Common Stock | 230K | 2K | 3K | 4K | 4K | 4K | 4K |
| Retained Earnings | -20.57M | -47.01M | -94.03M | -160.68M | -235.25M | -293.02M | -296.15M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 56K | 0 | 0 | -214K | 15K | 68K | 24K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RLYB Cash Flow Statement
Rallybio Corporation (RLYB) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -15.03M | -22.04M | -45.53M | -57.28M | -60.27M | -49.28M | -49.28M |
| Operating CF Margin % | - | - | - | - | - | -7748.74% | - |
| Operating CF Growth % | - | -46.67% | -106.6% | -25.81% | -5.2% | 18.22% | 120.5% |
| Net Income | -17.56M | -26.45M | -47.01M | -66.65M | -74.56M | -57.77M | -14.17M |
| Depreciation & Amortization | 26K | 62K | 109K | 167K | 150K | 131K | 119K |
| Stock-Based Compensation | 194K | 704K | 3.65M | 9.5M | 10.92M | 7.99M | 6.5M |
| Deferred Taxes | 103K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 144K | 1.52M | 1.5M | 640K | -1.05M | 627K | -21.84M |
| Working Capital Changes | 2.07M | 2.12M | -3.78M | -936K | 4.28M | -258K | -5.61M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 728K | 723K | -976K | 487K | -99K | -698K | -314K |
| Cash from Investing | -188K | -2.07M | -2.33M | -112.17M | 27.66M | 33.49M | 41.77M |
| Capital Expenditures | -188K | -137K | -333K | -54K | -12K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 0 | -1.94M | -2M | -300K | -2.25M | -2M | 20M |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | -1.94K | -2K | 0 | 2.25M | 0 | -1.5M |
| Cash from Financing | 31.57M | 144.89M | 82.97M | 51.08M | 143K | 5.2M | 28K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 143K | 1000K | 28K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 28K |
| Other Financing | -33K | -319K | -3.23M | -455K | 0 | -206K | 0 |
| Net Change in Cash | 16.35M▲ 0% | 120.78M▲ 638.5% | 35.1M▼ 70.9% | -118.38M▼ 437.2% | -32.46M▲ 72.6% | -10.59M▲ 67.4% | 6.8M▲ 0% |
| Free Cash Flow | -15.21M▲ 0% | -22.18M▼ 45.8% | -45.87M▼ 106.8% | -57.34M▼ 25.0% | -60.28M▼ 5.1% | -49.28M▲ 18.2% | -35M▲ 0% |
| FCF Margin % | - | - | - | - | - | -7748.74% | -5192.28% |
| FCF Growth % | - | -45.76% | -106.83% | -25.01% | -5.13% | 18.24% | 31.48% |
| FCF per Share | -5.47 | -7.98 | -11.42 | -14.41 | -11.92 | -9.05 | -9.05 |
| FCF Conversion (FCF/Net Income) | 0.85x | 0.83x | 0.97x | 0.86x | 0.81x | 0.85x | 2.47x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RLYB Key Ratios
Rallybio Corporation (RLYB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -34.6% | -30.17% | -38.65% | -54.13% | -68.85% | -25.22% |
| Return on Invested Capital (ROIC) | - | - | -89.97% | -60.72% | -69.81% | -69.81% |
| Gross Margin | - | - | - | - | 100% | 95.55% |
| Net Margin | - | - | - | - | -9084.12% | -2102.37% |
| Debt / Equity | - | - | 0.00x | 0.00x | 0.00x | 0.00x |
| Interest Coverage | -516.39x | -4564.80x | - | - | - | - |
| FCF Conversion | 0.83x | 0.97x | 0.86x | 0.81x | 0.85x | 2.47x |
| Revenue Growth | - | - | - | - | - | -18.4% |
RLYB Frequently Asked Questions
Rallybio Corporation (RLYB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rallybio Corporation (RLYB) reported $0.7M in revenue for fiscal year 2024.
Rallybio Corporation (RLYB) grew revenue by 0.0% over the past year. Growth has been modest.
Rallybio Corporation (RLYB) reported a net loss of $14.2M for fiscal year 2024.
Dividend & Returns
Rallybio Corporation (RLYB) has a return on equity (ROE) of -68.8%. Negative ROE indicates the company is unprofitable.
Rallybio Corporation (RLYB) had negative free cash flow of $35.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More RLYB
Rallybio Corporation (RLYB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates